ALPER TOPAL, MUSTAFA BAŞAK
The European Research Journal - 2025;11(5):858-867
Objectives: The classification of human epidermal growth factor receptor 2 (HER2)-low breast cancer has gained clinical relevance following the success of antibody-drug conjugates in this subgroup. However, its prognostic and predictive role, particularly in hormone receptor-positive (HR+) early breast cancer treated with neoadjuvant chemotherapy (NACT), remains unclear. This study aimed to evaluate the impact of HER2- low versus HER2-0 status on pathological complete response (pCR) and disease-free survival (DFS) in HR+ breast cancer patients undergoing NACT.
